IPSC
Century Therapeutics, Inc.Healthcare·Biotechnology
$2.45
$212M market cap
Revenue
$0.0M
Free Cash Flow
$-42.2M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102,
2-Year Price History
$2.26-23.9%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -22.5 | -25.5 | -21.6 | -25.2 | -25.8 | -0.6 | 134.8 | 43.9 | 86.6 | -50.9% | -- | -- |
| Act | 2025-Q4 | 0.0 | -17.1 | -20.7 | -19.2 | -16.1 | -16.4 | -0.3 | 117.1 | 43.6 | 86.6 | -86.5% | -- | -- |
Valuation & Metrics
Market Stats
Price$2.45
Market Cap$212M
Enterprise Value$121M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-19.9%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-40.8M
Free Cash Flow$-42.2M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-68.7%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares12.1M
Days to Cover13.8
Change (vs Prior)+9.9%
Need at least 2 settlement dates for chart
Employees
Headcount140
Revenue / Employee$0
Gross Profit / Employee$-21,457
Cash Runway
38.3months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
144.8%(+139.5% YoY)
60 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
11.3%(+9.5% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.3% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $40.1M | $2.26 | +$38.4M | +$40.1M | -4.4% | $9.44B |
| TCG Crossover Management, LLC | $39.0M | $2.26 | +$40.1M | +$39.0M | +4.6% | $3.50B |
| Versant Venture Management, LLC | $27.5M | $2.26 | +$27.5M | +$27.5M | -14.7% | $141M |
| Deep Track Capital, LP | $21.4M | $2.30 | +$20.2M | +$21.4M | -1.1% | $4.85B |
| Commodore Capital LP | $19.7M | $2.26 | +$19.7M | +$19.7M | -0.1% | $1.73B |
| RTW INVESTMENTS, LP | $19.7M | $2.26 | +$19.7M | +$19.7M | -2.2% | $9.26B |
| VR Adviser, LLC | $19.7M | $2.87 | +$14.0M | +$14.0M | -1.8% | $2.68B |
| Point72 Asset Management, L.P. | $13.5M | $1.01 | +$7K | +$13.5M | +0.9% | $54.88B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $12.9M | $2.26 | +$12.9M | +$12.9M | — | $4.04T |
| BALYASNY ASSET MANAGEMENT LLC | $11.3M | $2.26 | +$11.3M | +$11.3M | -0.4% | $48.01B |
| MILLENNIUM MANAGEMENT LLC | $10.5M | $2.13 | +$9.2M | +$10.5M | -0.5% | $127.40B |
| Spruce Street Capital LP | $9.2M | $1.82 | +$6.0M | +$9.2M | +53.1% | $416M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $8.6M | $2.19 | +$4.4M | +$8.6M | -0.1% | $64.61B |
| Woodline Partners LP | $6.9M | $2.26 | +$6.4M | +$6.9M | -0.1% | $26.43B |
| Seven Fleet Capital Management LP | $6.7M | $2.26 | +$6.7M | +$6.7M | +43.7% | $315M |
| Trails Edge Capital Partners, LP | $5.5M | $2.26 | +$5.5M | +$5.5M | +11.9% | $425M |
| DAFNA Capital Management LLC | $5.5M | $2.69 | −$812K | +$1.7M | -5.2% | $434M |
| TWO SIGMA INVESTMENTS, LP | $5.4M | $1.36 | +$2.0M | +$5.2M | -0.9% | $117.03B |
| BlackRock, Inc.Passive | $3.4M | $1.83 | +$2.1M | −$3.4M | -0.2% | $5.69T |
| Rock Springs Capital Management LP | $2.9M | $2.26 | +$2.9M | +$2.9M | -1.9% | $1.65B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+1.00%
avg per quarter
Holders (ex-self)
+0.92%
excl. this stock
Buyers (this Q)
+1.20%
42 buyers · $0.27B in
Sellers (this Q)
-4.75%
15 sellers · $-0.00B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
+2.9%
how holders react when this stock falls
On quiet Qs
-8.8%
−10% to +10% baseline
On rallies (+10%+)
-4.8%
how they react when this stock rises
Holders' portfolio flow this Q
+2.9%
inflows — adds are organic
Sellers' portfolio flow this Q
-9.3%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-1.4%
Holder mid (any stock)
-1.6%
Holder rally (any stock)
-6.7%
Biggest decreases this quarter
New buyers this quarter
TCG Crossover Management, LLC+$0.04Bα+4.6Versant Venture Management, LLC+$0.03Bα-14.7Commodore Capital LP+$0.02Bα-0.1RTW INVESTMENTS, LP+$0.02Bα-2.2VANGUARD CAPITAL MANAGEMENT LLC+$0.01BBALYASNY ASSET MANAGEMENT LLC+$0.01Bα-0.4Seven Fleet Capital Management LP+$0.01Bα+43.7Trails Edge Capital Partners, LP+$0.01Bα+11.9Rock Springs Capital Management LP+$0.00Bα-1.9VANGUARD FIDUCIARY TRUST CO+$0.00B
Top-5 holders · 47.8%
RA CAPITAL MANAGEMENT, L.P.--
TCG Crossover Management, LLC--
Versant Venture Management, LLC--
Deep Track Capital, LP--
Commodore Capital LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
FMR LLC9KCasdin Capital, LLC1.2MSB Management Ltd—RA CAPITAL MANAGEMENT, L.P.17.8MTCG Crossover Management, LLC17.8MAvidity Partners Management LP—FEDERATED HERMES, INC.—Logos Global Management LP—Versant Venture Management, LLC12.2MDeep Track Capital, LP9.5M
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$2.00-1840.0%
Last Year (2 analysts)$3.002240.0%
Current Price$2.45
Analyst Ratings
7
2
Buy: 7Hold: 2Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$97K
3 txns · 2 insiders · 145,060 sh
Sells ($, 12mo)
$69K
18 txns · 5 insiders · 65,221 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-05-04 | SELL | Carr Douglas | officer: SVP Finance & Operations | 264 | $2.34 | $618 | $1.19M |
| 2026-03-12 | SELL | Carr Douglas | officer: SVP Finance & Operations | 7,043 | $2.55 | $18K | $1.29M |
| 2026-03-12 | SELL | Russotti Gregory | officer: See Remarks | 10,076 | $2.55 | $26K | $1.31M |
| 2026-03-09 | SELL | Russotti Gregory | officer: See Remarks | 479 | $2.54 | $1K | $1.33M |
| 2026-02-03 | SELL | Carr Douglas | officer: SVP Finance & Operations | 323 | $1.82 | $589 | $938K |
| 2025-12-22 | BUY | Cowan Chad | officer: Chief Scientific Officer | 58,060 | $0.85 | $49K | $887K |
| 2025-12-12 | BUY | Pfeiffenberger Brent | director, officer: President and CEO | 52,000 | $0.58 | $30K | $1.94M |
| 2025-12-08 | SELL | Carr Douglas | officer: SVP Finance & Operations | 257 | $0.53 | $137 | $215K |
| 2025-12-08 | SELL | Russotti Gregory | officer: See Remarks | 526 | $0.53 | $280 | $208K |
| 2025-11-20 | SELL | Cowan Chad | officer: Chief Scientific Officer | 5,462 | $0.50 | $3K | $495K |
| 2025-11-19 | BUY | Pfeiffenberger Brent | director, officer: President and CEO | 35,000 | $0.50 | $17K | $1.62M |
| 2025-11-17 | SELL | Pfeiffenberger Brent | director, officer: President and CEO | 32,456 | $0.45 | $15K | $1.47M |
| 2025-11-03 | SELL | Carr Douglas | officer: SVP Finance & Operations | 292 | $0.59 | $171 | $237K |
| 2025-09-08 | SELL | Carr Douglas | officer: SVP Finance & Operations | 263 | $0.50 | $132 | $203K |
| 2025-09-08 | SELL | Pfeiffenberger Brent | director, officer: President and CEO | 488 | $0.50 | $244 | $1.63M |
| 2025-09-08 | SELL | Russotti Gregory | officer: See Remarks | 539 | $0.50 | $270 | $196K |
| 2025-08-04 | SELL | Carr Douglas | officer: SVP Finance & Operations | 296 | $0.53 | $158 | $217K |
| 2025-06-09 | SELL | Carr Douglas | officer: SVP Finance & Operations | 4,904 | $0.62 | $3K | $253K |
| 2025-06-09 | SELL | Farid Adrienne | officer: Chief Operations Officer | 552 | $0.62 | $343 | $156K |
| 2025-06-09 | SELL | Pfeiffenberger Brent | director, officer: President and CEO | 475 | $0.62 | $295 | $1.05M |
Order Flow (FINRA, ~3w lag)
22.8%retail+2.0pp
25.0%dark+0.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Century Therapeutics: A Ghost Ship Propelled by Non-Cash Paper Profits
Overall Risk
8/10
Fraud
3/10
Dilution
7/10
Insolvency
7/10
Earnings Overstated
9/10
Hidden Liabilities
4/10
Legal
2/10
Audit Warnings
5/10
Hidden Upside
2/10
Contextually Acceptable
3/10